Biosig technologies, inc. (BSGM)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-14,748

-12,060

-12,695

-9,526

-9,263

-12,276

-11,587

-12,237

-10,322

-8,991

-9,461

-10,044

-14,382

-10,408

-8,473

0

0

0

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization

67

54

40

24

17

12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity based compensation

16,920

15,177

9,953

8,382

8,881

6,600

7,952

7,612

4,577

4,749

1,685

1,940

5,441

5,999

6,513

7,768

7,452

7,968

8,688

10,528

7,034

5,743

0

0

0

Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC

0

-

-

-

0

-

-

-

-

543

543

543

543

0

0

0

0

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

11

11

11

10

10

10

10

10

10

11

12

14

15

0

0

0

Changes in operating assets and liabilities:
Inventory

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Vendor deposits

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

122

90

129

171

37

61

-4

-8

-42

-17

15

33

150

102

50

-41

-55

-44

-16

76

-21

-8

0

0

0

Payment of long term deposit

-

-

-

-

-

-37

-42

-31

5

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

436

537

262

724

259

478

-838

-1,022

-241

102

877

972

354

149

82

0

-96

-333

-102

-219

-224

-110

0

0

0

Lease liability, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

593

0

0

0

Lease liability, net

-

-

-

-

-

-

530

644

584

210

64

-31

-528

-422

-743

2,090

2,845

3,113

0

0

0

-

-

-

-

Stock based payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-226

0

132

646

226

0

0

0

Deferred rent payable

-

-

-

-

-

-2

-0

0

1

2

2

1

0

0

-0

-3

-3

-3

-2

0

0

1

0

0

0

Net cash used in operating activities

-17,902

-15,482

-14,550

-13,100

-11,390

-10,255

-9,540

-8,814

-8,247

-7,470

-6,478

-5,794

-5,549

-5,107

-4,936

-4,720

-4,471

-4,523

-3,892

-3,603

-2,711

-1,997

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of patent costs

52

111

152

121

327

268

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of trademark costs

0

0

0

1

1

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

183

177

99

75

48

38

24

16

11

9

10

12

17

16

18

12

13

15

8

12

6

3

0

0

0

Net cash used in investing activity

-233

-285

-252

-198

-377

-307

-253

-274

-11

-9

-10

-12

-17

-16

-18

-12

-15

-18

-11

-15

-6

-3

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock

10,440

10,007

8,619

12,490

17,488

9,139

11,030

8,240

4,481

6,011

6,293

5,741

6,674

5,226

4,771

4,241

2,069

4,759

3,474

4,278

4,782

1,969

0

0

0

Proceeds from sale of Series E preferred stock

-

-

-

-

-

-

-

-

145

29

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of Series E preferred stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of options

-

-

-

-

-

615

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net repayments of related party advances

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-30

0

0

0

Net cash provided by financing activities

22,702

23,427

19,832

19,958

21,666

13,465

16,838

11,881

8,049

7,971

6,573

5,981

6,674

5,226

4,771

4,241

2,565

5,255

3,970

4,774

4,771

1,938

0

0

0

Net increase in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

2,792

-209

491

83

175

1,106

102

-184

-491

-1,921

713

65

1,155

2,053

-62

0

0

0

Supplemental disclosures of cash flow information:
Cash paid during the period for interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

12

3

11

11

0

0

0

Cash paid during the period for income taxes

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Noncash investing and financing activities:
Reclassify derivative liability to equity

-

-

-

-

-

3,044

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Dividend payable on preferred stock charged to additional paid in capital

19

25

124

314

590

884

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Right-to-use assets and lease liability recorded upon adoption of ASC 842

0

422

422

422

422

0

0

0

0

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Series C Preferred Stock [Member]
Common stock issued upon conversion preferred stock and accrued dividends

415

399

399

546

716

744

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Embedded Derivative Financial Instruments, Upon Issuance of Series D Preferred Stock [Member]
Reclassify derivative liability to equity

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Upon Adoption of ASU 2017-11 [Member]
Reclassify derivative liability to equity

-

-

-

-

-

3,044

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-